Will MAP0004 successfully meet the needs of Migraineurs as well as or, hopefully, better than current abortive medication options? That remains to be seen, but thus far, it looks quite promising.
____________
Resources:
1 Press Release. "MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting." Mountainview, California. MAP Pharmaceuticals. June 28, 2008.
2 Press Release. "MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine." Mountainview, California. MAP Pharmaceuticals. July 14, 2008.
3 Research Poster Presentation. "Newer Acute Migraine Specific Drugs May Provide Improved Sustained Relief and Freedom Over 24 and 48 Hours Post Dosing." American Headache Society 50th Annual Scientific Meeting in Boston, MA. June, 2008.
4 Research Poster Presentation. "Assessment of QTc Effect of DHE When Delivered Via the Lung by the Tempo Inhaler." American Headache Society 50th Annual Scientific Meeting in Boston, MA. June, 2008.
5 Research Poster Presentation. "MAP0004, an Orally Inhaled Formulation of DHE, Delivers Faster and More Consistent Blood Levels of the Drug Compared to Traditional Oral, Subcutaneous, Intramuscular, and Intranasal Formulations of DHE." American Headache Society 50th Annual Scientific Meeting in Boston, MA. June, 2008.
6 Research Poster Presentation. "Systemic Pharmacokinetics of DHE When Delivered Via the Lung to Asthmatics by the Tempo Inhaler." American Headache Society 50th Annual Scientific Meeting in Boston, MA. June, 2008.
7 Personal interview by Teri Robert. Dr. Shashidhar H. Kori, Vice President of Clinical Development, MAP Pharmaceuticals. August 12, 2008.
8 Personal interview by Teri Robert. Timothy S. Nelson, President and CEO of MAP Pharmaceuticals. August 12, 2008.
© Teri Robert, 2008
Last updated August 18, 2008.
